ZESTORETIC (lisinopril and hydrochlorothiazide) by Almatica Pharma is mechanism of action lisinopril inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension, to lower blood pressure. First approved in 1989.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
ZESTORETIC is a fixed-dose oral combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic) approved in 1989 for hypertension management. Lisinopril inhibits angiotensin-converting enzyme to reduce vasoconstriction and aldosterone secretion, while hydrochlorothiazide increases sodium and chloride excretion to lower blood volume and peripheral resistance. This dual mechanism provides complementary antihypertensive effects with the diuretic offsetting potassium elevation from the ACE inhibitor.
Product approaching loss of exclusivity with modest Medicare spending signals contraction phase; expect focus on manufacturing efficiency and generic transition planning rather than market expansion.
Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the…
Thiazide Diuretic
Worked on ZESTORETIC at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Careers linked to ZESTORETIC are concentrated in technical, manufacturing, and supply chain operations rather than commercial or medical roles, reflecting a mature product transitioning toward generic manufacturing. Opportunities favor operations, quality assurance, and regulatory compliance professionals supporting the existing formulation rather than innovation or market expansion teams.
13 open roles linked to this drug
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo